AHB(SH:688639) Zhi Tong Cai Jing·2026-02-27 14:29Core Viewpoint - Huaheng Biological (688639.SH) expects a revenue of 2.886 billion yuan for the fiscal year 2025, representing a year-on-year increase of 32.50%, while the net profit attributable to the parent company is projected to be 131 million yuan, reflecting a year-on-year decrease of 30.97% [1] Group 1: Financial Performance - The company anticipates a revenue of 2.886 billion yuan for 2025, which is a 32.50% increase compared to the previous year [1] - The expected net profit attributable to the parent company is 131 million yuan, indicating a decrease of 30.97% year-on-year [1] Group 2: Industry Context - The amino acid and vitamin industries are experiencing a phase of supply-demand imbalance, leading to intense market competition [1] - The average prices of the company's main products, valine and myo-inositol, have decreased compared to the same period last year [1] Group 3: Operational Challenges - The benefits of new projects have not yet materialized, impacting the company's profitability [1] - As the company expands its operational scale, various expenses have increased compared to the previous year, contributing to the overall decline in profit [1]